Supplement for managing canine OA is launched in the US market

Image courtesy of epiq Animal Health

A nutraceutical for enhancing canine joint health is launching in the US animal health market. The supplement (4CYTE Epiitalis Forte Dog) is distributed by epiq Animal Health in partnership with Interpath Global, a research and development company for animal joint health, is derived from plant seed oil that is high in unique fatty acids.¹

The US release of the supplement for canines, “4CYTE Dog,” follows the December 2024 launch of a companion equine gel product (4CYTE Epiitalis Forte Horse), “4CYTE Horse.” The supplement for horses was made available to the US market in December 2024 with a product launch at the American Association of Equine Practitioners conference in Orlando, Florida, according to an email from epiq Animal Health.

4CYTE Dog and 4CYTE Horse are formulated with the patented ingredient Epiitalis Forte, a natural plant seed oil that is sustainably sourced, according to epiq Animal Health. Both 4CYTE and Epiitalis have undergone “rigorous” assessments for safety and efficacy including clinical trials with various species that include dogs, horses and humans.¹

In a 2020 pilot study of 4CYTE Dog, for example, investigators at the University of Melbourne in Australia found 93.5% of the 50 enrolled canines with naturally occurring osteoarthritis (OA) used the supplement for managing the condition and demonstrated improvement in quality of life, with 74% showing mobility improvement by day 28. Investigators of the pilot study concluded the supplement was successful in reducing OA symptoms in dogs.²

Both the canine and equine supplements were previously made available abroad through other distributors, according to the epiq email. These supplements have been sold in Australia, where they were developed, and have also found markets in Canada, New Zealand, and the United Kingdom.

Rebecca Britton, general manager of Interpath Global, said 4CYTE products for dogs and horses have been scientifically proven to enhance joint health function in horses and dogs, and epiq is excited to bring it to the US market. “The feedback from horse and dog owners around the world and, most importantly, the exceptional clinical outcomes for the animals themselves are second to none," Britton said in a news release.¹

Both supplements are now available to US customers through animal health technology and services provider Covetrus, while agreements with additional animal health product distributors are pending. The supplement for dogs can also be purchased online through Amazon. Additionally, the supplement for horses is available online through the equine supplies market SmartPak, a subsidiary of Covetrus.¹

Reference

1. epiq Animal Health and Interpath Global launch second joint health product offering—this one for the dogs. News release. epiq Animal Health. April 17, 2025. Accessed April 17, 2025. https://www.prnewswire.com/news-releases/epiq-animal-health-and-interpath-global-launch-second-joint-health-product-offering--this-one-for-dogs-302428970.html
2. Beths T, Munn R, Bauquier SH, Mitchel P, Whittem T. A pilot study of 4CYTE™ Epiitalis® Forte, a novel Nutraceutical, in the management of naturally occurring osteoarthritis in the dog. University of Melbourne. Accessed April 17, 2025. https://minerva-access.unimelb.edu.au/rest/bitstreams/de9c78e3-0d67-549c-b888-7fd0b0cee6ba/retrieve